Hank

Other Medications

Experimental

Not available 1 Clinical Trials

Description

Hank is an investigational medication being studied for colorectal cancer. It is being evaluated in clinical trials, specifically in phase 1b/2 studies, for patients with metastatic colorectal cancer who have already received standard treatments. These trials are exploring Hank's potential use, sometimes in combination with other therapies like regorafenib or other investigational agents. The trials are designed to assess safety and determine if Hank shows signs of effectiveness in this patient population. Hank is not currently approved for treating colorectal cancer.

Mechanism of Action

Hank is being investigated as part of a cancer vaccine approach (NANT CRC Vaccine). The specific way Hank works (its mechanism of action) is still being studied in clinical trials. It is designed to stimulate the body's immune system to target cancer cells.

Side Effects

As Hank is an investigational drug in early-phase trials (Phase 1b/2) The full range of potential side effects is still being evaluated. Information about specific side effects from these trials is limited. Patients participating in these trials are closely monitored for any adverse events.

Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.

Clinical Trials

NCT03563157 Phase 1

Archived

QUILT 3.071: NANT Colorectal Cancer (CRC) Vaccine

United States

Quick Info

Category	Other Medications
EMA Status	Experimental
Spain Access	Not available
Clinical Trials	1

View Clinical Trials Back to Drug Glossary

Related Medications

Medical Disclaimer

This information is for educational purposes only and should not replace professional medical advice. Always consult your healthcare team before making treatment decisions.